Interaction Checker

Interaksi Sorafenib

Sorafenib (Nexavar) memiliki 210 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 38 mayor, 172 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (38)

  • AksitinibMayor

    Fatal cerebrovascular accident was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib [see Adverse Reactions (6.1) ] . (label Aksitinib, Peringatan dan perhatian)

  • Aprepitantpenghambat CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • EfavirenzantiretroviralMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • EtravirinantiretroviralMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • FenitoinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • FenobarbitalbarbituratMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • GemsitabinantimetabolitMayor

    NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (label Sorafenib, Peringatan dan perhatian)

  • GriseofulvinantijamurMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • KarboplatinMayor

    • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (label Sorafenib, Kontraindikasi)

  • KlobazambenzodiazepinMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Modafinilstimulan SSPMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • NeomisinaminoglikosidaMayor

    Avoid concomitant use of NEXAVAR with neomycin. (label Sorafenib, Interaksi obat)

  • NevirapinantiretroviralMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • PaklitakselMayor

    • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (label Sorafenib, Kontraindikasi)

  • PrimidonantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • RifabutinantibiotikMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • RifampisinantibiotikMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • RifapentinantibiotikMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • RitonavirantiretroviralMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • SenobamatantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • SisplatinMayor

    NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (label Sorafenib, Peringatan dan perhatian)

  • Suzetriginpenginduksi CYP3A4Mayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

  • TopiramatantikonvulsanMayor

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (label Sorafenib, Interaksi obat)

Interaksi moderat (172)

  • AdenosinantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Alfuzosinpenyekat alfaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • AliskirenantihipertensiModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Amiloriddiuretik hemat kaliumModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • AmiodaronantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Amitriptilinantidepresan trisiklikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Amlodipinpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Anagrelidobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Arsen trioksidaobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Asebutololpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • AsenapinantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Atenololpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Atenolol dan klortalidonpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Azilsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Azitromisinantibiotik makrolidaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Benazeprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Benazepril dan hidroklorotiazidpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Betaksololpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Bisoprololpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Bisoprolol dan hidroklorotiazidpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Dekstrometorfan dan kuinidinobat serotonergikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Deutetrabenazinpenghambat VMAT2Moderat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Digoksinglikosida digitalisModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Diltiazempenghambat kanal kalsiumModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • DisopiramidantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • DofetilidantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Doksazosinpenyekat alfaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • DronedaronantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Droperidolantagonis dopaminModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Enalaprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Enalaprilatpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Eplerenonantagonis aldosteronModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Eritromisinantibiotik makrolidaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • EsitalopramSSRIModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Esmololpenyekat betaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Fenoksibenzaminpenyekat alfaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • FingolimodimunosupresanModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • FlekainidantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Flukonazolantijamur azolModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • FluoksetinSSRIModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Fosinoprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Furosemiddiuretik loopModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Granisetronobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Guanfasinagonis alfa-adrenergikModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • HaloperidolantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • HidralazinvasodilatorModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Hidroklorotiaziddiuretik tiazidModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Hidroksiklorokuinobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • HidroksizinantihistaminModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • IbutilidantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • IloperidonantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Irbesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Isosorbid dinitrat dan hidralazinnitratModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Kandesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Kaptoprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Ketokonazolantijamur azolModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Klaritromisinantibiotik makrolidaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Klonidinagonis alfa-adrenergikModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • KlorokuinantimalariaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Klorotiaziddiuretik tiazidModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • KlorpromazinantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • KlozapinantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • KuetiapinantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Kuinaprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • KuinidinantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • KuininantimalariaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Labetalolpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • LevofloksasinfluorokuinolonModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Levotiroksinhormon tiroidModerat

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (label Sorafenib, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidModerat

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (label Sorafenib, Peringatan dan perhatian)

  • Lidokainanestetik lokalModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Lidokain dan prilokainanestetik lokalModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Liotironinhormon tiroidModerat

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (label Sorafenib, Peringatan dan perhatian)

  • Lisinoprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Lofeksidinagonis alfa-adrenergikModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Loperamidobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Losartanpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • MekamilaminantihipertensiModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • MeksiletinantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • MetadonopioidModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • MetildopaantihipertensiModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Metolazondiuretik tiazidModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Metoprololpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Metoprolol dan hidroklorotiazidpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • MinoksidilvasodilatorModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Moeksiprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • MoksifloksasinfluorokuinolonModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Nadololpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Nebivololpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Nikardipinpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Nilotinibobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • NitroprusidvasodilatorModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • OfloksasinfluorokuinolonModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Olanzapin dan fluoksetinantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Olmesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Ondansetronobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • PaliperidonantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Pentamidinobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Perindoprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • PimavanserinantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • PimozidantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Pindololpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Pitolisantobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Posakonazolantijamur azolModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Prazosinpenyekat alfaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • ProkainamidantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • PrometazinantihistaminModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Prometazin dan dekstrometorfanantihistaminModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Prometazin dan kodeinopioidModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • PropafenonantiaritmiaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Propiltiourasilobat antitiroidModerat

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (label Sorafenib, Peringatan dan perhatian)

  • Propranololpenyekat betaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Ramiprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Ranolazinobat yang memperpanjang interval QTModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • RisperidonantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Sakubitril dan valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • SiprofloksasinfluorokuinolonModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • SitalopramSSRIModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • SolifenasinantikolinergikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Sotalolpenyekat betaModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • TakrolimusimunosupresanModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Tamoksifenmodulator reseptor estrogen selektifModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Telmisartanpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Terazosinpenyekat alfaModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Teriparatidhormon tiroidModerat

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (label Sorafenib, Peringatan dan perhatian)

  • Tetrabenazinpenghambat VMAT2Moderat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Tiamazolobat antitiroidModerat

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (label Sorafenib, Peringatan dan perhatian)

  • TioridazinantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Tizanidinpelemas ototModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • TolterodinantikolinergikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Torasemiddiuretik loopModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Toremifenmodulator reseptor estrogen selektifModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • TramadolopioidModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Tramadol dan parasetamolopioidModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Trandolaprilpenghambat ACEModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • TrazodonantidepresanModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Valbenazinpenghambat VMAT2Moderat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Vardenafilpenghambat PDE5Moderat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • VenlafaksinSNRIModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Verapamilpenghambat kanal kalsiumModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Vorikonazolantijamur azolModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • WarfarinantikoagulanModerat

    Increased Risk of Bleeding with Concomitant Use of Warfarin Infrequent bleeding or elevations in the International Normalized Ratio (INR) have been reported in some patients taking warfarin while on NEXAVAR. (label Sorafenib, Peringatan dan perhatian)

  • ZiprasidonantipsikotikModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

Periksa Sorafenib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.